High patient satisfaction for ocular hypotensives

Article

Glaucoma and ocular hypertension (OHT) patients are highly satisfied with ocular hypertensives, claims a recent investigation.

Glaucoma and ocular hypotension patients are highly satisfied with ocular hypotensives, claims a recent investigation.

A prospective, observational, cohort study, led by Professor Helen Danesh-Meyer, Department of Ophthalmology, University of Auckland, New Zealand, included 2541 patients with glaucoma or ocular hypotension. The Treatment Impact Patient Satisfaction Scale (TIPSS) was mailed to all patients during a three-month study period.

The questionnaire evaluated patient demographics topical ocular hypotensive use, number of medications used, frequency of administration, ease of use, class of medication, presence/severity of side effects, impact on quality of life and patient satisfaction. The main outcome measure was patient satisfaction and this was determined via univariate and multivariate analyses.

Of the patients who responded to the questionnaire, almost 80% claimed they were either 'very satisfied' or 'satisfied' with topical ocular hypotensives. Factors that affected patient satisfaction were identified as satisfaction with frequency of eye drop use, subjective convenience and ease of administration.

Overall, glaucoma and ocular hypotension patients are satisfied with topical ocular hypotensive medications. However, patient satisfaction could be further improved by focusing on medication convenience and ease of administration.

The abstract can be found in the latest issue of Clinical and Experimental Ophthalmology.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.